Geron Corporation To Present At Rodman & Renshaw Techvest Global Healthcare Conference
Menlo Park, CA – May 11, 2004 –– Geron Corporation (Nasdaq: GERN) will be presenting an update of the company’s product development programs on Thursday, May 13, 2004, at the Rodman & Renshaw Techvest Global Healthcare Conference in London at 9:05 a.m. BST (British Summer Time).
The review of Geron’s portfolio of telomerase–based anti–cancer therapies includes GRN163 and GRN163L and the ex vivo telomerase vaccine. The presentation will also include updates on the company’s latest human embryonic stem cell (hESC) research in spinal cord injury, diabetes and heart disease. Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer, will be giving the presentation.
The audio and slide presentation will be available at the following website address: http://www.rodmanandrenshaw.com. Go to the Techvest Global Healthcare Conference page and click on Conference Schedule. The webcast will be archived for 30 days.
For further information, please contact Geron Corporation at 650–473–7765, or visit Rodman & Renshaw’s website at www.rodmanandrenshaw.com.
Geron is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic products for cancer based on its telomerase technology, and cell–based therapeutics using its human embryonic stem cell technology.
Contact: Geron Corporation Investor and Public Relations Tel: 650–473–7765
Additional information about the company can be obtained at http://www.geron.com
